Concepedia

Author

W. Brugger

University Medical Center Freiburg

Also Known As

W Brugger, W Brügger, W. Brugger, Wolfram Brugger

22

Publications

572

Citations

9

H-Index

30

Concepts

All Affiliations

University Medical Center Freiburg
WB

About

W. Brugger is an author at University Medical Center Freiburg specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

128

2

Cell Biology

2

2

37

3

Health Sciences

1

1

23

4

Cellular Therapies

1

1

14

5

Immunology

1

1

14

W. Brugger

×

9

Publications

545

Citations

9

H-Index

YearCitations

Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin

W. Brugger, W Mocklin, S Heimfeld,

Blood

1993

324

Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC

W. Brugger, Nadja Triller, Maria Błasińska-Morawiec,

Journal of Clinical Oncology

2009

57

Ex vivo expansion of hematopoietic progenitor cells for clinical use.

Stefan Scheding, Karsten Kratz‐Albers, Bernhard Meister,

PubMed

1998

36

CT and MR Features of Primary Pulmonary Hemangiopericytomas

Martin Halle, Ernst Dinkel, W. Brugger

Journal of Computer Assisted Tomography

1993

33

Final Evaluation of a Phase II Study on the Effect of Edelfosine (an Ether Lipid) in Advanced Non-Small-Cell Bronchogenic Carcinoma

P. Drings, I Günther, U. Gatzemeier,

Oncology Research and Treatment

1992

24

In vivo biology and therapeutic potential of hematopoietic growth factors and circulating progenitor cells.

F. Herrmann, W. Brugger, Lothar Kanz,

PubMed

1992

23

Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limiteddisease small cell lung cancer

W. Brugger, H. Frommhold, R Mertelsmann,

Lung Cancer

1995

21

Correlation analyses between CD34+ cells and clonogenic progenitors mobilized into the peripheral blood by IL-3 + GM-CSF following polychemotherapy in cancer patients

Lothar Kanz, W. Brugger, K. Bross,

Stem Cells

1992

14

9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC

W. Brugger, J.-H. Kim, Olfred Hansen,

European Journal of Cancer Supplements

2009

13

Page 1